Eton Pharmaceuticals
ETON is a specialty pharma focused on rare disease treatments (notably pediatric and endocrine), offering exposure to high-margin orphan markets where pricing power and limited competition can drive outsized operating leverage.
Key Catalysts
Breakout Revenue Growth: Q4 2025 sales +83% YoY to $21.3M and full-year revenue more than doubled, reflecting strong execution on launches and niche indication expansion.
Portfolio Expansion Adds 2026 Fuel:
DESMODA (oral liquid desmopressin) launch expands the endocrine franchise.
HEMANGEOL acquisition strengthens the commercial base and adds a meaningful revenue contributor into 2026.
Profitability Inflection: 2026 guidance implies $110M+ revenue with 30%+ EBITDA margins, signaling powerful operating leverage as scale builds.
Orphan-Drug Playbook: Focused M&A in underserved rare diseases supports pricing durability, limited competitive pressure, and multiple near-term catalysts.
Investment Outlook
Bullish above: $20.50–$21.00
Upside target: $33.00–$34.00, driven by accelerating product sales, portfolio expansion, and margin expansion into 2026.
Key Catalysts
Breakout Revenue Growth: Q4 2025 sales +83% YoY to $21.3M and full-year revenue more than doubled, reflecting strong execution on launches and niche indication expansion.
Portfolio Expansion Adds 2026 Fuel:
DESMODA (oral liquid desmopressin) launch expands the endocrine franchise.
HEMANGEOL acquisition strengthens the commercial base and adds a meaningful revenue contributor into 2026.
Profitability Inflection: 2026 guidance implies $110M+ revenue with 30%+ EBITDA margins, signaling powerful operating leverage as scale builds.
Orphan-Drug Playbook: Focused M&A in underserved rare diseases supports pricing durability, limited competitive pressure, and multiple near-term catalysts.
Investment Outlook
Bullish above: $20.50–$21.00
Upside target: $33.00–$34.00, driven by accelerating product sales, portfolio expansion, and margin expansion into 2026.
Wyłączenie odpowiedzialności
Informacje i publikacje nie stanowią i nie powinny być traktowane jako porady finansowe, inwestycyjne, tradingowe ani jakiekolwiek inne rekomendacje dostarczane lub zatwierdzone przez TradingView. Więcej informacji znajduje się w Warunkach użytkowania.
Wyłączenie odpowiedzialności
Informacje i publikacje nie stanowią i nie powinny być traktowane jako porady finansowe, inwestycyjne, tradingowe ani jakiekolwiek inne rekomendacje dostarczane lub zatwierdzone przez TradingView. Więcej informacji znajduje się w Warunkach użytkowania.
